


CALR Mutation Screening Kit

- Detection of 36 different Calreticulin (CALR) Gene mutations.
- Superior analytical sensitivity and specifity with Allele Spesfic PCR.
- Fast and Easy use with Multiplex Realtime PCR Technology.



RUO











SENSITIVE



QUALITATIVE

The geneMAP $^{\text{TM}}$ CALR Screening Kit is a qualitative in vitro assay for the detection of 36 CALR somatic mutations from human genomic DNA of subjects suspected of myeloproliferative neoplasms (MPN) and also allows the identification of the two major CALR mutations (Type 1 and Type 2).


Simple real time - PCR Workflow



Sample preparation Add DNA to the reaction mix



qPCR amplificationMultiplex qPCR using primers
designed to amplify the DNA
sequences specific to each SNP
of interest



Data interpretationSNPs are identified by allele-specific real time PCR.





Validated PCR Instruments

- Bio-Rad CFX96
- Life Technologies ABI-7500, QuantStudio Series
- Roche, Light Cycler 480 II
- Qiagen Rotor-Gene® 3000 Q5/Q6
- BioMolecular Systems, MicPCR
- BaseTyper™, Pentabase


Ordering Information CALR-RT25 geneMAP™ CALR Mutation Screening Kit 25 tests **RUO**


CE-IVD is available in the EU and countries outside EU accepting the CE-IVD certification.

Available as RUO in all other countries.

Technical Specifications

Qualitative in vitro assay for the detection of Calreticulin Somatic Mutations from human genomic DNA and also for identifying two major CALR mutations (Type 1 and Type 2).





CONTENTS	VOLUME
4x CALR Type Primer Probe Mixes	2 x 125 µl
4x CALR Del Primer Probe Mixes	3 x 125 µl
2x Master Mixes	3 x 500 µl
RNase Free Water	400 μΙ
Positive Control	125 µl

In GENMARK SAGLIK URUNLERI, we aim to create the top quality, time and cost efficient, trust-worthy and user-friendly products. We specialize in in-vitro detection kit production and development which is used for the diagnosis and treatment monitoring of many diseases connected to genetics, oncology, microbiology and hematological oncology.



